Evidence map›Paper›PMID 16550210›Full record

ReviewThe pharmacogenomics journal

Clinical implications of pharmacogenomics of statin treatment.

L M Mangravite, C F Thorn, R M Krauss

Abstract readReview
PubMed Publisher
In one paragraph

Review in The pharmacogenomics journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.Journal of the American College of Cardiology · 2009
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

L M MangraviteDepartment of Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
C F Thorn
R M Krauss

Funding

Pharmacogenomics and Risk of Cardiovascular DiseaseU01HL069757 · NHLBI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI KRAUSS, RONALD M · 2001 to 2009
$24.7M
THE STANFORD PHARMACOGENETICS KNOWLEDGE BASEU01GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2000 to 2009
$24.0M
NHLBI NIH HHS U-01 HL-69757NIGMS NIH HHS U-01 GM-61374
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PharmacogeneticsCytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMembrane Transport ProteinsOrganic Anion Transporterscytochrome P-450 CYP2C subfamilyCytochrome P-450 CYP3ACytochrome P-450 Enzyme SystemHydroxymethylglutaryl-CoA Reductase InhibitorsMembrane Transport ProteinsOrganic Anion Transporters

Identifiers

PMID16550210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.